Association of regulatory T-Cell Expansion with progression of amyotrophic lateral sclerosis a study of humans and a transgenic mouse model

RK Sheean; FC McKay; E Cretney; CR Bye; ND Perera; D Tomas; RA Weston; KJ Scheller; E Djouma; P Menon; SD Schibeci; N Marmash; JJ Yerbury; SL Nutt; DR Booth; GJ Stewart; MC Kiernan; S Vucic; BJ Turner

Journal article

Association of regulatory T-Cell Expansion with progression of amyotrophic lateral sclerosis a study of humans and a transgenic mouse model

RK Sheean, FC McKay, E Cretney, CR Bye, ND Perera, D Tomas, RA Weston, KJ Scheller, E Djouma, P Menon, SD Schibeci, N Marmash, JJ Yerbury, SL Nutt, DR Booth, GJ Stewart, MC Kiernan, S Vucic, BJ Turner

JAMA Neurology | AMER MEDICAL ASSOC | Published : 2018

DOI: 10.1001/jamaneurol.2018.0035

Abstract

IMPORTANCE Neuroinflammation appears to be a key modulator of disease progression in amyotrophic lateral sclerosis (ALS) and thereby a promising therapeutic target. The CD4+Foxp3+ regulatory T-cells (Tregs) infiltrating into the central nervous system suppress neuroinflammation and promote the activation of neuroprotective microglia in mouse models of ALS. To our knowledge, the therapeutic association of host Treg expansion with ALS progression has not been studied in vivo. OBJECTIVE To assess the role of Tregs in regulating the pathophysiology of ALS in humans and the therapeutic outcome of increasing Treg activity in a mouse model of the disease. DESIGN, SETTING, AND PARTICIPANTS This pros..

View full abstract

University of Melbourne Researchers

Related Projects (2)

SMN IMMUNOGENE THERAPY FOR MOTOR NEURON DISORDERS

We have designed novel gene therapy agents to treat MND. This therapeutic approach uniquely combines gene therapy agents with antibodies whi..

TARGETING AUTOPHAGY TO IMPROVE PROTEIN METABOLISM IN ALS

One common feature of MND is the accumulation of protein deposits inside nerve cells which leads to their death. We have identified a potent..

Grants

Awarded by Motor Neurone Disease Research Institute of Australia

Funding Acknowledgements

Funding/Support: This article was supported by grants from the Australian National Health and Medical Research Council (grants 1104295 and 1104299, Dr Turner; grant 1047313, Dr Cretney), Stafford Fox Medical Research Foundation, MND Research Institute of Australia, Vowell Foundation, and Margaret Dawn Marks Charitable Trust Fund. Additional funding came from Forefront, a collaborative research group supported from the National Health and Medical Research Council of Australia (grant 1037746, Dr Kiernan). Drs Sheean, Bye, Weston, Scheller, and Turner and Ms Tomas, via their affiliation with the Florey Institute of Neuroscience and Mental Health, and Drs McKay, Booth, Stewart, and Vucic, and Mr Schibeci, via their affiliation with theWalter and Elisa Hall Institute, are supported by the Victorian Government and the Operational Infrastructure Support Grant. Dr Perera is supported by an Australian Postgraduate Award Scholarship.